Experimental Parkinson's drug talineuren put to early safety test
NCT ID NCT04976127
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety of an intravenous drug called talineuren (liposomal GM1) in 22 people with Parkinson's disease. The study was open-label and designed to find a safe dose, but it was terminated before completion. No conclusions about effectiveness can be drawn from this small, preliminary study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
talineuren (liposomal GM1)
What this could lead to
If successful, this could point toward a new add-on therapy to help manage Parkinson's symptoms alongside standard treatment.
What could go wrong
This was a very early Phase 1 safety trial with only 22 participants, and it was terminated early. It is too small and preliminary to draw any conclusions about effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neurologisches Institut Konolfingen
Konolfingen, Canton of Bern, 3510, Switzerland